

Viscum Album - Literature Review

Ana Catarina Viana Valle^{1,2*}, Aloisio Cunha de Carvalho¹, Rosangela Vieira Andrade²

¹Doctor Izaio Soares Institute – Integrative Medicine, Ribeirao Preto, Brazil

²Catholic University of Brasilia – Brasilia, Brazil

*Corresponding author: [dranacatarina\[at\]gmail.com](mailto:dranacatarina[at]gmail.com)

Abstract: *Viscum album L., popularly known as "Mistletoe", is considered a semi-parasitic plant that grows on several host trees. It has a wide variety of biologically active compounds that can be used to treat various diseases, being its most significant indication for the adjuvant treatment of cancer patients. However, little data is found in the literature on the in vitro and in vivo effects of Viscum album (VA), although formulations for commercial use are available, with extremely low doses of its active compounds. Previous studies used anthroposophical VA and provided information on the mechanisms of action of this extract in tumor and immune system cells. Therefore, the objective of this study was to perform a literature review on the VA plant regarding its botanical behavior and action in cancer patients.*

Keywords: Mistletoe, literature review, cancer patients

1. Introduction

The use of *Viscum album* (VA) as a medicine dates back to the ancient Celtic people, being incorporated into popular medicine after the Middle Ages and included among the homeopathic medical matters in the 19th century. In the 20th century, VA was frequently approached by Rudolf Steiner (1861-1925) and Ita Wegmann (1876-1943) around 1917, within the scope of the emergence of the Anthroposophical Medicine, when it was related to the treatment of tumor diseases. These scholars considered that the active therapeutic ingredient would have to be extracted in two seasons (summer and winter) to obtain the therapeutic action more efficiently (LEGNANI, 2008), taking into account the defense system of the plant and the synthesis of various substances throughout the seasons (VALLE, 2008). The first publication on this topic is dated 1933 (KAELIN, 1933).

Over time, different forms of VA extract preparations were performed, such as aqueous, hydroalcoholic, ethanolic extract, among others (DELEBINSKI *et al.*, 2015; ÜNGER, 1987). The observed pharmaceutical effects are generally more detectable with the use of whole extracts rather than the use of purified lectins and viscotoxins alone (LICHOTA; GWOZDZINSKI, 2018). Its therapeutic action was demonstrated as being an immunomodulator, apoptosis inducer, and having a cytotoxic activity (SZURPNICKA *et al.*, 2020).

Classical studies show that viscotoxins can increase the amount of circulating natural killer (NK) cells and consequently improve the anti-tumor immune response (TABIASCO *et al.*, 2002). Similarly, viscotoxin has an effective immunomodulatory effect on human and animal granulocytes (SÁRPATAKI *et al.*, 2014; GIUDICI *et al.*, 2003) besides acting on cellular apoptosis (KAUCZOR *et al.*, 2012). The viscotoxin cytotoxic action is comparable to that of conventional chemotherapy agents (WEISSENSTEIN *et al.*, 2014; VAN WELY *et al.*, 1999;

KUTTAN *et al.*, 1990).

Within this context, the use of homeopathic medicines prepared from plant extracts is highlighted, which have been experimentally studied in Brazil and other countries (BONAMIN *et al.*, 2015; ENDLER *et al.*, 2010). However, no data on the effects of the prepared VA commercial formulations, which present very low doses of their active ingredients, is found in the literature (CARVALHO, 2015). The published experimental studies record punctual information on the mechanisms of action of this medicine in tumor or immune system cells. However, the cytotoxic, apoptotic, and immunologic aspects of VA are not demonstrated in the papers.

2. Literature Review

Viscum album

Botanical characteristics

Viscum album, also called Mistletoe, Muerdago, Visco, or white Visco (Figure 1-A, E), belongs to the *Loranthaceae* and *Viscaceae* families, which are related to the Santalales order. The *Viscaceae* family has seven genera: *Arceuthobium*, *Dendrophthora*, *Ginalloa*, *Korthalsella*, *Notothixos*, *Phoradendron*, *Viscum*, and various other genera worldwide (URECH; BAUMGARTNER, 2015; BUSSING, 2000; BARLOW, 1983). The European *Viscum* (*Viscum album* L.) is an evergreen, perennial, and hemiparasitic plant (URECH; BAUMGARTNER, 2015; ELLURU *et al.*, 2009; KIENLE *et al.*, 2007; BUSSING, 2000; BARLOW, 1983). This plant is widely distributed throughout Europe. Male and female plants live as hemiparasites of woody trees, from which they obtain water and inorganic compounds dissolved directly from the xylem. Insects pollinate the discrete flowers (Figure 1 – C). The mature pseudofruits (Figure 1 – D) are dispersed by various birds, being the most important way of dispersing their seeds (URECH; BAUMGARTNER, 2015; BARLOW, 1983), as shown in figure 1.



Figure 1: (A and E) Adult plant of a *Viscum album* species; (B) haustory, (C) Flowering; (D) Fruits. Source: A and B images Zone (2020). Images C and D Mistletoe (2020). Image E, author's collection

The VA plant can colonize a large number of host trees, such as fir (*Abies*), almond (*Prunus dulcis*), hawthorn (*Crataegus*), ash (*Fraxinus*), elm (*Ulmus*), willow (*Salix alba*), pine (*Pinus*), apple tree (*Malus mali*), poplar (*Populus*), or oak (*Quercus*), the last three being the main growth sites of VA (URECH; BAUMGARTNER, 2015; NICKRENT, 2002; BUSSING, 2000).

The mistletoe is a small shrub with linear and lanceolar leathery leaves that persist for several seasons. Its yellowish-green flowers and develop translucent and whitish berries in late autumn and early winter. VA does not grow on land but is spread to tree trunks by birds whose excreta contain seeds. Unlike other plants, VA has a vegetation period of 12 months, never touches the land, and blooms during the winter (URECH; BAUMGARTNER, 2015; NICKRENT, 2002; BUSSING, 2000).

Viscum album is attached to a host branching a primary haustory (Figure 1 - B), described as a modified radicle. During germination and once in contact with the host/surface, the radicle tip becomes expanded and flattened to form an adhesive disc (RUBIALES; HEIDE-JØRGENSEN 2011). When contact with the host is established, the outermost cell layer (epidermis) develops a growth point (meristem) (URECH; BAUMGARTNER, 2015; NICKRENT, 2002; BUSSING, 2000). Each leaf supports a bud, which produces the growth increase for the next year. The number of subsequent internodes reveals the approximate age of the plant. It takes 2-4 years to germination occurs, endophyte establishes, and leaf starts its development. The leaves are perennial (NICKRENT, 2002; BUSSING, 2000).

Bioactive Compounds

It is challenging to identify all active phytochemicals compounds present in the *Viscum album* plant. A broad

spectrum of different compounds has been described, such as proteins, polysaccharides, oligosaccharides, steroids, triterpenes, flavonoids, alkaloids, lipophilic molecules (SZURPNICKA et al., 2019; URECH; BAUMGARTNER, 2015; AMER et al., BUS0709 et al., BUS0709 et al., BUS0709 2000), syringin (PANOSSIAN et al., 1998), viscumneoside XII, viscumneoside XIII, viscumneoside XIV (DAI et al., 2019), and conjugated acetylene compounds (CAO et al., 2019). It is widely reported that the plant's main effects are derived from lectins and low molecular weight proteins, such as viscotoxins, which were described around 1950 (BUSSING, 2000; URECH; BAUMGARTNER, 2015). Viscotoxins (VTs) are thionines and are classified in alpha and beta. They are rich in cysteine, proteins with a low molecular weight of approximately 5kD (TABIASCO et al., 2002; BUSSING, 2000; SCHALLER et al., 1996), and are resistant to protease (TABIASCO et al., 2002). However, seven more forms were identified, such as VT A1, A2, A3, B, (TABIASCO et al., 2002; BOGOMOLOVAS et al., 2009; SCHALLER et al., 1996) B2, C1, and OS, each with a chain of 46 amino acids with homologous sequences. Thirty-two of 46 positions have identical amino acids, and all forms have three disulfide bridges (Cys3/Cys40, Cys3/Cys32, and Cys16/Cys26), providing a compact structure. This characteristic probably explains the high stability regarding denaturation (URECH; BAUMGARTNER, 2015).

Analysis of the 3D structure of the VTs produced information about a specific phosphate-binding site. This bond and the amphipathic structure of the VT must interfere with the cell membrane and destroy its integrity, generating cytotoxic effects (ORRÙ et al., 1997). First, stimulating necrosis and a minor induction of apoptosis (BÜSSING, 2000). Interestingly, despite their identical structure, VTs present a different biological behavior in the three VA species (SHALLER et al., 1996). The VTs micromolar

concentrations are cytotoxic to the targets; the bioactivity concerning NK lysis is within the nanomolar range and differs among the viscotoxin isoforms: VTA1 (85 nm), VTA2 (18 nm), and VTA3 (8 nm).

According to Senthikumar and Rajasekaran (2017), VTs can be considered promising antimicrobial compounds that belong to the antimicrobial peptides (AMP) family. These authors tested the different VTs for their antimicrobial potential and concluded that VTA3 has a better efficacy since several physicochemical characteristics demonstrated its antimicrobial peptide stability among the available VTs. Knowledge of how this peptide establishes its conformation represents the first step in determining the mechanisms adjacent to its antimicrobial activity and in the planning of rational treatments. It is suggested that the rigid nature and stability of a VT peptide framework make it useful in planning for new medicines. A study demonstrated the VTA3 stable structure provided by various physicochemical parameters and the S-S bonds that made this VT a model for potential peptide therapies (SENTHILKUMAR & RAJASEKARAN, 2017).

As stated by Tabiasco *et al.* (2002), VTs have an immunomodulatory capacity. Therefore, the authors demonstrated that when VTs are administered in non-toxic concentrations, they may increase the death of tumor cells, mediated by NK cells. In its turn, they spare non-target cells from NK lysis, showing a specific selectivity, which is still unknown. Additionally, Tabiasco *et al.* (2002) indicate that, within such non-toxic concentrations, VTs do not activate NK cells but act in cellular conjugates to increase the resulting lysis. The authors also reported that VTs micromolar concentrations might be cytotoxic to targets, and their bioactivity concerning NK lysis is within the nanomolar range and differs among the VT isoforms A1, A2, A3.

Lectins are carbohydrate-binding proteins with various activities, such as anti-tumor and immunomodulatory effects (KOVACS *et al.*, 2000; LYU; PARK, 2007), such as increased phagocytic activities and the release of cytokines by granulocytes and monocytes (KOVACS *et al.*, 2000). These substances are proposed as potentials, in biological and therapeutic research, due to their interactions with glycans bound to receptors on cell surfaces, responsible for primary cell signaling and biological responses (SOUZA *et al.*, 2013). In particular, lectins can induce the activation of several immune cells through the binding of Toll-like receptors (TLRs). They can also induce the secretion of cytokines (IL-10 and IL-12) through the activation of macrophages and dendritic cells by connection to TLR2 (PANUNTO-CASTELO *et al.* 2001; COLTRI *et al.*, 2008).

Three different types of ML lectins were identified in VA: MLI (115kDa) - galactose, MLII (60kDa) - galactose and N-acetyl-D-galactosamine, and MLIII (60kDa) - N-acetyl-D-galactosamine (JUNG *et al.*, 1990; AHMED *et al.*, 2018; BUSSING, 2000; URECH; BAUMGARTNER, 2015). These lectins belong to the type 2 ribosome inactivation protein consisting of a protein with B subunit and a toxophoric chain A, an N-glycosidase RNA. ML blocks protein synthesis by hydrolysis of 28S rRNA in the

ribosome of eukaryotic cells, inducing apoptosis. The amino acid sequence of tertiary and quaternary structures of the MLI and the A chain of the MLIII is not yet fully understood (AHMED *et al.*, 2018).

The biological action exerted by lectins is considered to be somewhat limited due to their high toxicity. Park *et al.* (2000) reported that VA lectin could induce nitric oxide production and secretion of TNF- α in macrophages. However, although ML has several biological and immunological activities, its use is limited in cancer therapy or as an adjuvant due to its toxicity to normal cells.

Viscum album polysaccharides are found among fruits and green parts of the plant (leaves and stems). High methylation of galacturonan, pectin with a molecular weight of 42kD, and arabinogalactan, with a molecular weight of 110kD, were isolated from stems and leaves (JORDAN, WAGNER, 1986). Fruits are especially rich in polysaccharides and contain rhamnogalacturonan, arabinogalactans (above 1, 340kD), and small amounts of xyloglucans (EDLUND *et al.*, 2000). The high molecular weight of arabinogalactan selectively stimulates the proliferation of CD4+ T helper lymphocytes (STEIN & BERGER 1999) and stimulates NK cells (MÜLLER; ANDERER, 1990). A recent study by Chai and Zhao (2017) describes the anti-tumor activity of VA-derived polysaccharides. Such activity supposedly occurred through the apoptosis induction by the interference in the G1 phase of the cell cycle and was observed in hepatocarcinoma cells.

Viscum album is a plant rich in triterpenes, betulinic acid (FUKUNAGA *et al.*, 1987), oleanolic acid, ursanolic acid (WAGNER *et al.*, 1984), and lupeol acetate (URECH *et al.*, 2006; ORHAN *et al.*, 2006). Stigmasterol phytosteroid and beta-sitosterol are also present in the VA extracts (URECH *et al.*, 2006). Lipophilic extracts contain saturated oils, such as palmitic, arachidonic, lignoceric, and cerotic acids, and unsaturated oils, such as linoleic and linolenic acids (URECH *et al.*, 2006; ORHAN *et al.*, 2006).

Stammer *et al.* (2017) mentioned that oleanolic acid and its derivatives inhibit *in vitro* cell proliferation and induce cell apoptosis. Moreover, *in vivo* experiments demonstrated the cytotoxic effect of oleanolic acid on gallbladder carcinoma cells (LI *et al.*, 2015), hepatocellular carcinoma (YANG ET AL., 2012), and pancreatic carcinoma (WEI *et al.*, 2012). Due to their low solubility, triterpene acids do not occur in significant amounts in the VA commercially produced extracts (JAGER *et al.*, 2007). However, the use of cyclodextrins potentiated the solubilization of triterpene acids, overcoming the loss in standardized aqueous extracts. Previous studies have shown the effectiveness of a combined mistletoe extract produced by adding solubilized triterpene and fatty acids (TT) to aqueous VA extracts, creating a whole plant extract added with triterpenes (viscumTT). This whole plant extract effectively induced apoptosis in acute and lymphoblastic myeloid leukemia (DELEBINSK *et al.*, 2015), Ewing's sarcoma (TWARDZIOK *et al.*, 2017), and osteosarcoma (KLEINSIMON *et al.*, 2017), and also inhibited tumor growth in *in vivo* murine melanoma cells (STRUH *et al.*, 2012).

Flavonoids (HÄNSEL *et al.*, 1994; FUKUNAGA *et al.*, 1987; BECKER; EXNER, 1980), phenylpropanoids (FUKUNAGA *et al.*, 1987; WAGNER *et al.*, 1984), and alkaloids (KHWAJA *et al.*, 1986; KHWAJA *et al.*, 1980) represent the group of the most abundant substances in the plant kingdom and are present in the VA. Several pieces of evidence of their pharmacological roles in various pathologies are responsible for the growing interest of the scientific community (LORCH, 1993). The first description of flavonoids present in VA dates 1955. After that date, some subtypes were discovered, such as aglycahomoeriodictiol, sakuranetin, rhamnazin, and isorhamnetin (BECKER; EXNER, 1980; FUKUNAGA *et al.*, 1987; HÄNSEL *et al.*, 1994). However, there are no data available in the literature for most of these subtypes. Becker and Exner (1980) studied the flavonoid patterns of the VA subspecies being quercetin and a series of methyl ether of quercetin, which can be accumulated in the plant (WOLLENWEBER *et al.*, 2000). Other authors have also reported some flavanones and chalcones as constituents of this plant (WOLLENWEBER *et al.*, 2000).

According to Panossian *et al.* (1998), four phenylpropanoids were isolated from the VA extract, such as coniferin, syringin, and syringenin. The structures were established based on spectral and chemical data. They also describe these substances' biological activities, such as the ability to inhibit ADP-induced platelet aggregation, inhibit leukotriene B₄ release from TPA, and from human granulocytes stimulated with calcium ionophore A-23187, as well as an anti-tumor activity associated with protein kinase C (PKC) inhibition. The alkaloids present in the VA extracts are not considered typical alkaloids and are reported as "alkaloids-like" including tyramine, phenylethylamine, choline, and acetylcholine (BUSSING, 2000). Other components of VA include carbohydrates such as homogalacturonan, pectin, arabinogalactan, and rhamnogalacturonan. In addition, the contents of the plant (monosaccharides and polyols) were evaluated after acid hydrolysis. The results varied depending on the host tree (quercus pine). The compounds inositol and galactose were dominant in the pines, with 58% and 44% dry weight (JORDAN, WAGNER, 1986).

Cao *et al.* (2019) identified two new conjugated acetylene compounds, dibutyl (2Z, 6Z)-octa-2, 6-dien-4-yne dioate and dibutyl (2E, 6E)- octa-2, 6-dien-4-yne dioate. The mechanism of action of these two substances was evaluated by the antioxidant activity of the compounds and used the xanthine oxidase inhibitory activity test, obtaining satisfactory results.

Furthermore, Dai *et al.* (2019) reported three new flavonoid glycosides, called viscumneoside XII, viscumneoside XIII, and viscumneoside XIV, which were isolated from the aerial part of the *V. album* plant. Their structures were identified by spectroscopic data analysis. Also, the cytotoxicity assay showed these flavonoids had significant inhibitory activities against C6, A549, and MDA-MB-231 (the inhibition rate reached about 50%, 70%, and 74%, respectively, with $IC_{50} \leq 60.00 \mu\text{mol}\cdot\text{L}^{-1}$), while the inhibition of TF-1 and Hela was not significant, with approximately 10% inhibition. A549, TF-1, Hela, MDA-MD-231, and C6 cell lines were obtained from the Shanghai cell bank. All tests were

performed in duplicate with positive control with doxorubicin hydrochloride.

***Viscum album* and its action in cancer patients**

Since ancient times, VA has been used in Europe to treat various diseases by conventional and complementary medicines (LONGHI *et al.*, 2020; LOEF; WALACH, 2020). Since 1917 VA preparations have been administered in therapy against cancer and are considered the most used treatment by complementary medicine for cancer patients (FELENDÁ *et al.*, 2019).

Therapy with VA is indicated for the treatment of cancer patients in a curative and/or palliative way with increasing frequency (KAESTNER *et al.*, 2019; MENKE *et al.*, 2019). It is considered the most frequently prescribed medication among German doctors (ROSTOCK, 2020; MATTHES *et al.*, 2020), including among pediatricians (MENKE *et al.*, 2020). In Europe, more than 88% of cancer patients opt for complementary therapies, and 77% of them use therapy with VA (MATTHES *et al.*, 2020).

The administration of VA extracts have already been described in the treatment of medulloblastoma (MENKE *et al.*, 2020), cholangiocarcinoma (VALLE *et al.*, 2019), transmissible venereal tumor (VALLE *et al.*, 2019), melanoma (STRÜH *et al.*, 2012; WERTHMANN *et al.*, 2017; MELO *et al.*, 2018; VALLE *et al.*, 2020), cervical carcinoma in situ (REYNEL *et al.*, 2018), carcinoma pancreatic (SCHAD *et al.*, 2013; WERTHMANN *et al.*, 2018), renal carcinoma (WEI *et al.*, 2013; WERTHMANN *et al.*, 2019), squamous cell carcinoma (KLINGBEIL *et al.*, 2013), bladder carcinoma (URECH *et al.*, 2006), hepatocellular carcinoma (YANG *et al.*, 2012; WANG; ZHANG, 2013; KUMAR *et al.*, 2016; YANG *et al.*, 2019), ewing's sarcoma (TWARDZIOK *et al.*, 2017), myeloma (KOVACK *et al.*, 2012; VALLE *et al.*, 2018), aoveolar rhabdomyosarcoma (STAMMER *et al.*, 2017), glioma and glioblastoma (SCHÖTTERL *et al.*, 2019), neuroblastoma (DELEBINSKI *et al.*, 2011; KAESTNER *et al.*, 2019), gastric carcinoma (KIM *et al.*, 2012), among others.

Viscum album has bidirectional activity in the treatment against cancer, showing a direct relationship in terms of improving the patients' quality of life (KAESTNER *et al.*, 2019; LOEF; WALACH, 2020) by reducing fatigue, exhaustion, nausea, vomiting, depression, anxiety, pain, and side effects caused by conventional therapies, thereby improving the patient's sleep and appetite (KAESTNER *et al.*, 2019). It also demonstrates anti-tumor activity by selective cytotoxicity (VALLE *et al.*, 2020), induction of apoptosis (HAN *et al.*, 2015), and inhibition of angiogenesis (ELLURU *et al.*, 2009) by mechanisms of action not well elucidated until this moment.

Oei *et al.* (2019) describes that the anti-cancer activity demonstrated by VA is linked to its immunomodulatory activity, such as increased maturation and activation of dendritic cells (STEINBORN *et al.*, 2017), increase in leukocytes, eosinophils, granulocytes (HUBER *et al.*, 2011) and lymphocytes, increased cytokine secretion (ELLURU *et al.*, 2009), and increased natural killer cell activity (KIM *et*

al., 2012).

Melo *et al.* (2018) demonstrated and identified that some secondary metabolites, such as the phenolic compounds present in VA extracts, presented anti-cancer activity against B16F10 and K562 tumor cell lines, showing selective tumor effect, cytotoxicity with apoptosis induction, and effect on the cell cycle. Moreover, the authors propose that the identified compounds are the possible contributors to the antiproliferative and apoptotic effects of VA, suggesting an interesting potential for cancer pharmacotherapy.

According to Oei *et al.* (2020), the impact of oncological therapies in the reports of patients with breast cancer without the occurrence of metastasis is very significant and stressful in the long term. Chemotherapy and immunotherapy are included as points that increase fatigue, decrease thermal balance, and affect physical functioning. In its turn, their research showed that the co-administration of VA to conventional treatments had better effects in reducing fatigue, insomnia, and the physical activity itself, as well as in thermoregulation. Therefore, they concluded that complementary therapies with VA administration could be indicated to relieve and decrease the burden of clinical signs during conventional treatments for breast cancer.

Kaestner *et al.* (2019) described a decrease of neuroblastoma tumors in patients submitted only to chemotherapy treatment. However, a reduction in their quality of life was also observed. They also observed that, despite being subjective, the quality of life of patients undergoing chemotherapy treatment associated with VA therapy could be preserved for a long time, even after the disease's recurrence or progression.

3. Conclusion

Viscum album has been used for centuries for different purposes. It includes various preparation forms, such as extracts, teas, and creams by the traditional medicine with its simple herbal preparations, or by the anthroposophic medicine or homeopathy with more complex forms of preparation. Its variety of bioactive compounds is notorious, and its complex range of pharmacological activities that have not been deeply studied yet. This plant is gaining more relevance each day in *in vitro* and *in vivo* studies mainly due to its cytotoxic and immunomodulatory activities. It is a medicine with bidirectional activity when administered to cancer patients since it stimulates the vital forces of the organism, improving immunity, and has a selective cytotoxic activity for tumor cells. Therefore, due to its satisfactory clinical area results, *Viscum album* is receiving much attention from the scientific community. This review sought to gather as much information about the *Viscum album* plant regarding its botanical characteristics, bioactive compounds, and activity in cancer patients. Although known for a long time, few scientific evidences of the plant effects in the molecular field are known. Therefore, this is a new field for further studies by the scientific community concerning the isolation and identification of bioactive compounds, pharmacologic activities, interactions, and synergy among compounds and possible mechanisms of

action. It is a new field for science that should be explored, given all its clinical evidence and proven clinical activity.

References

- [1] Ahmad MS, Rasheed S, Falke S, Khaliq B, Perbandt M, Choudhary MI, et al. Crystal Structure of Mistletoe Lectin I (ML-I) from *Viscum album* in Complex with 4-N-Furfurylcytosine at 2.85 Å Resolution. *Med Chem.*, [S.I.], 2018, v. 14, n. 8, p. 754-763.
- [2] AmerB, Juvik OJ, Dupont F, Francis GW, Fossen T. Novel aminoalkaloids from European mistletoe (*Viscum album* L.). Elsevier BV. *Phytochemistry Letters*, [S.L.], set. 2012, v. 5, n. 3, p. 677-681.
- [3] Barlow BA. Biogeography of Loranthaceae and Viscaceae. [S.I]: Csrio, 1983. p. 19-46.
- [4] Becker H, Exner J. Vergleichende Untersuchungen von MistelnverschiedenerWirtsbäume an Hand der Flavonoide and Phenolcarbonsäuren: Comparative Studies of Flavonoids and Phenylcarboxylic Acids of Mistletoes from Different Host Trees. Elsevier, [S.I.], maio, 1980, v. 97, n. 5, p. 417-428.
- [5] Bell IR, Sarter B, Standish LJ, Banerji P, Banerji P. Low Doses of Traditional Nanophytomedicines for Clinical Treatment: manufacturing processes and nonlinear response patterns. *Journal Of Nanoscience And Nanotechnology*, [S.L.], American Scientific Publishers, 1 jun. 2015, v. 15, n. 6, p. 4021-4038.
- [6] Bogomolovas J, Simon B, Sattler M, Stier G. Screening of fusion partners for high yield expression and purification of bioactive viscotoxins. *Protein Expression And Purification*, [S.L.], Elsevier BV. mar. 2009, v. 64, n. 1, p. 16-23.
- [7] Büssing A . Mistletoe: The Genus *Viscum*. Amsterdam: Harwood Academic Publ. 2000.
- [8] Cao d, Wang Li-Qing, Han Xiao-Min, Guan Hui-Rui, Lei M, Wei Ya-Hui, et al. Two sym metrical unsaturated acids isolated from *Viscum album*. *Chinese Journal Of Natural Medicines*, [S.L.], Elsevier BV, fev. 2019, v. 17, n. 2, p. 145-148.
- [9] Carvalho C, et al. Canine neurofibrosarcoma treatment with *Viscum album* in serial dilutions. *Int J High Dilution Res. Bern (Switzerland)*, ago. 2013, p. 0-1.
- [10] CARVALHO, A, C.; Antineoplastic activity of *Viscum album* (L) in experimental tumors: a critical review and experimental study in Ehrlich tumor. Doctorate Dissertation in Environmental and Experimental Pathology, UniversidadePaulista, 2015. 72p.
- [11] Chai Y, Zhao M. ITRAQ-Based Quantitative Proteomic Analysis of the Inhibitory Effects of Polysaccharides from *Viscum coloratum* (Kom.) Nakai on HepG2 Cells. *Sci Rep*, [S.I.], jul. 2017, v. 4, n. 7, p. 1-10.
- [12] Chikramane PS, Suresh AK, Bellare JR, Kane SG. Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective. *Homeopathy*, [S.I.], out. 2010, v. 99, n. 4, p. 231-242.
- [13] Coltri KC, Oliveira LL, Pinzan CF, Vendruscolo PE, Martinez R, Goldman MH, et al. Therapeutic Administration of KM+ Lectin Protects Mice Against

- Paracoccidioidesbrasiliensis Infection via Interleukin-12 Production in a Toll-Like Receptor 2-Dependent Mechanism. The American Journal of Pathology, Elsevier BV, [S.L.], ago. 2008, v. 173, n. 2, p. 423-432.
- [14] Dai, Jia-Kun, et al. Three new bioactive flavonoid glycosides from *Viscum album*. Chin J Nat Med, [S.I.], jul. 2019. v. 7, n. 17, p. 545-550.
- [15] DELEBINSKI, Catharina *et al.* Effects of *Viscum album* L. extracts in neuroblastoma in vitro and in vivo. Phytomedicine: International Journal OfPhytotherapy & Phytopharmacology, [S.I.], v. 18, n. 13, p. 1-19, 2011.
- [16] DelebinskiCI, JägerS, Kemnitz-HassaninK, Henze, G, Lode, HN.Seifert G. A Natural Combination Extract of *Viscum album* L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo. Plos One, [S.L.], 5 ago. 2015, v. 10, n. 8, p. 1-20.
- [17] Edlund U, Hensel A, Fröse D, Pfüller U, Scheffler A. Polysaccharides from Fresh *Viscum album* L. Berry Extract and Their Interaction with *Viscum album* Agglutinin I. Arzneimittelforschung, Georg Thieme Verlag KG. [S.L.], 27 dez. 2011., v. 50, n. 07, p. 645-651.
- [18] ElluruSR, Van Huyen JPD, DelignatS, Prost F, HeudesD, Kazatchkine MD, et al.Antiangiogenic properties of *Viscum album* extracts are associated with endothelial cytotoxicity. Anticancer Res., [S.I.], ago, 2009, v. 29, n. 8, p. 2945-2950.
- [19] FelendaJE.TurekC, Stintzing FC. Antiproliferative potential from aqueous *Viscum album* L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells. Journal of Ethnopharmacology, Elsevier BV, [S.L.], maio 2019, v. 236, p. 100-107.
- [20] Franz H , ZiskaP, Kindt A.Isolation and properties of three lectins from mistletoe (*Viscum album* L.). Biochemical Journal, [S.I.], abr. 1981, v. 195, n. 2, p. 481-484.
- [21] FukunagaT, Kajikawa I, NishiyaK, Watanabe Y, Takeya K, Itokawa H. Studies on the constituents of the european mistletoe, *Viscum album* L. Pharmaceutical Society of Japan. Chemical & Pharmaceutical Bulletin, [S.L.], 1987, v. 35, n. 8, p. 3292-3297.
- [22] Giudici M, Pascual R, Canal L de la, Pfuller K, Pfuller U, Villalaín J. Interaction of Viscotoxins A3 and B with Membrane Model Systems: implications to their mechanism of action. Elsevier BV. Biophysical Journal, [S.L.], ago. 2003, v. 85, n. 2, p. 971-981.
- [23] Haas K, Bauer M, Wollenweber E. Cuticular Waxes and Flavonol Aglycones of Mistletoes. Walter de Gruyter GmbH. ZeitschriftFür Naturforschung C, [S.L.], 1 ago. 2003, v. 58, n. 7-8, p. 464-470.
- [24] Han SY, Hong CE, Kim HG. et al. Anti-cancer effects of enteric-coated polymers containing mistletoe lectin in murine melanoma cells in vitro and in vivo. Molecular and Cellular Biochemistry volume 408, pages73–87(2015).
- [25] Hänsel R, Rimpler H, Keller K, Schneider G, Abel G, Bader G. HagersHandbuch der Pharmazeutischen Praxis. Springer Berlin Heidelberg. Springer-Verlag Berlin Heidelberg, [S.L.], jan. 1994, v. 5, n. -, p. 1160-1183.
- [26] Huber R, Lütke H, Wieber J, Beckmann C. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. Springer Science and Business Media LLC. BMC Complementary and Alternative Medicine, [S.L.], nov. 2011, 24, v. 11, n. 1, p. 1-12.
- [27] JägerS, Winkler K, PfüllerU, Scheffler A. Solubility Studies of Oleanolic Acid and Betulinic Acid in Aqueous Solutions and Plant Extracts of *Viscum album* L. Planta Medica, [S.I.], mar. 2017, v. 3, n. 2, p. 157-162.
- [28] Jiang Y, Zhang Li, RupasingheHPV. Antiproliferative effects of extracts from *Salvia officinalis* L. and *Salvia miltiorrhiza* Bunge on hepatocellular carcinoma cells. Biomed Pharmacother., [S.I.], jan. 2017, v. 85, n. -, p. 57-67.
- [29] Jordan; W. Detection and quantitative determination of lectins and viscotoxins in mistletoe preparations. Arzneimittelforschung., [S.I.], mar. 1986, v. 36, n. 3, p. 428-433.
- [30] Jung ML, BaudinoS, Ribéreau-GayonG, Beck, JP.Characterization of cytotoxic proteins from mistletoe (*Viscum album* L.). Elsevier- Cancer Letters, [S.I.], 30 maio 1990, v. 51, n. 2, p. 103-108.
- [31] Kaelin W, Die VDK. Hippokrates Z. prakt. Heilkunde 4, 325, 1933.
- [32] Kaestner J, Schlodder D, Preussler C, Gruhn B. Supportive mistletoe therapy in a patient with metastasised neuroblastoma. Bmj Case Reports, [S.L.], mar. 2019, v. 12, n. 3, p. 1-5.
- [33] Kauczor G, Delebinski C, Jäger S, Seeger K, Seifert G. Triterpene acid containing *Viscum album* L. extracts mediate apoptosis in paediatric solid cancer cells. Springer Science and Business Media LLC. BMC Complementary and Alternative Medicine, [S.L.], v. 12, n. 1, p. 1-2, jun. 2012.
- [34] Khwaja TA, Dias CB, Pentecost S. Recent Studies on the Anticancer Activities of Mistletoe (*Viscum album*) and Its Alkaloids. S. Karger AG. Oncology, [S.L.], 1986, v. 43, n. 1, p. 42-50.
- [35] KhwajaTA, VarvenJC, Pentecost S, PandeH. . Isolation of biologically active alkaloids from Korean mistletoe *Viscum album*, coloratum. Experientia., [S.I.], 15 maio 1980, v. 36, n. 5, p. 599-600.
- [36] Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res., [s. l.], mar. 2007, v. 12, n. 3, p. 103-119.
- [37] Kim KC, YookJH, EisenbraunJ, Kim BS, Huber R.. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study. BMC Complementary Medicine and Therapies, [S.I.], 3 out. 2012, v. 12, n. 172, p. 1-7.
- [38] KleinsimonS, KauczorG, Jaeger S, Eggert A, Seifert G, Delebinski C. *Viscum*TT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. BMC

- Complement Altern Med, [S.I], 7 jan. 2017, v. 17, n. 26, p. 1-13.
- [39] Klingbeil MFG, Xavier FCA, Sardinha LR, Severino P, Mathor MB, Rodrigues R V.. Cytotoxic effects of mistletoe (*Viscum album* L.) in head and neck squamous cell carcinoma cell lines. *Oncol Rep*, [S.I], nov.2013, v. 30, n. 5, p. 2316-2322.
- [40] Kovacs E. Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with *Viscum album* extract. *Elsevier BV. Biomedicine & Pharmacotherapy*, [S.L.], jul. 2000, v. 54, n. 6, p. 305-310.
- [41] Kovacs E. The Effects of *Viscum album* (Mistletoe) QuFrF Extract and Vincristine in Human Multiple Myeloma Cell Lines - A Comparative Experimental Study Using Several and Different Parameters. *Cancer Immunology Research*, [s. l], 12 mar. 2012. v. 2, n. 1, p. 588-606.
- [42] Kumar N, Biswas S, Mathew AE, Varghese S, Mathew JE, Nandakumar K, et al. Pro-apoptotic and cytotoxic effects of enriched fraction of *Elytrantheparasitica* (L.) Danser against HepG2 Hepatocellular carcinoma. *Springer Science and Business Media LLC. BMC Complementary and Alternative Medicine*, [S.L.], 26 out. 2016, v. 16, n. 1, p. 1-11.
- [43] Kuttan G, Vasudevan DM, Kuttan R. Effect of a preparation from *Viscum album* on tumor development in vitro and in mice. *Journal of Ethnopharmacology*, [S.L.], abr. 1990, v. 29, n. 1, p. 35-41.
- [44] Legnani W. Mistletoe in conventional oncological practice: exemplary cases. *Integr Cancer Ther*, [S.I], set. 2008, v. 7, n. 3, p. 162-171.
- [45] Lichota GK. Anti-cancer Activity of Natural Compounds from Plant and Marine Environment. *MDPI AG. International Journal of Molecular Sciences*, [S.L.], 9 nov. 2018, v. 19, n. 11, p. 1-38.
- [46] Li HF, Wang XA, Xiang SS, Hu YP, Jiang L, Shu YJ. Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells. *Drug Des Devel Ther.*, [S.I], 12 jul. 2015, v. 9, n. -, p. 3017-3030.
- [47] Lyu SY, P WB. Effects of Korean mistletoe lectin (*Viscum album coloratum*) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes. *Arch Pharm Res.*, [S.I], out. 2007, v. 30, n. 10, p. 1252-1264.
- [48] Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. *BMC Complementary Medicine and Therapies*, [S.I], jul. 2020, v. 20, n. -, p. 1-14.
- [49] Longhi A, Cesari M, Serra M, Mariani E. Long-Term Follow-up of a Randomized Study of Oral Etoposide versus *Viscum album Fermentatum Pini* as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. *Sarcoma*, [S.L.], 27 abr. 2020, v. 2020, p. 1-9.
- [50] Lorch E. Neue Untersuchungen über Flavonoide in *Viscum album ssp. abietis, album und austriacum*. *Z. Naturforsch.* 1993, 48c, 105-107.
- [51] Matthes H, Thronicke A, Hofheinz RD, Baars E, Martin D, Huber R. Statement to an Insufficient Systematic Review on *Viscum album* L. Therapy. *Evidence-Based Complementary and Alternative Medicine*, [S.L.], 18 fev. 2020, v. 2020, p. 1-9.
- [52] Melo MNO, Oliveira AP, Wicikowski AF, Carvalho RS, Castro JL, Oliveira FAG de, et al. Phenolic compounds from *Viscum album* tinctures enhanced anti-tumor activity in melanoma murine cancer cells. *Elsevier BV. Saudi Pharmaceutical Journal*, [S.L.], mar. 2018, v. 26, n. 3, p. 311-322.
- [53] Menke K, Schwermer M, Schramm A, Zuzak TJ. Preclinical Evaluation of Antitumoral and Cytotoxic Properties of *Viscum album* Fraxini Extract on Pediatric Tumor Cells. *Planta Med.*, [S.I], v. 85, n. 14, p. 1150-1159, out. 2019.
- [54] Menke K, Schwermer M, Eisenbraun J, Schramm A, Zuzak TJ. Anticancer Effects of *Viscum album* Fraxini Extract on Medulloblastoma Cells in vitro. *S. Karger AG. Complementary Medicine Research*, [S.L.], p. 1-8, 13 jul. 2020.
- [55] Mueller EA, Anderer FA. A *Viscum album* oligosaccharide activating human natural cytotoxicity is an interferon γ inducer. *Cancer Immunology Immunotherapy*, [S.L.], v. 32, n. 4, p. 221-227, jul. 1990. Springer Science and Business Media LLC.
- [56] Nguyen XN, Kiem PV, Minh CV, Kim Nanyoung, Parque Seonju, Lee HY. Diarylheptanoids and flavonoids from *Viscum album* inhibit LPS-stimulated production of pro-inflammatory cytokines in bone marrow-derived dendritic cells. *J Nat Prod.*, [S.I], 26 abr. 2013, v. 76, n. 4, p. 495-502.
- [57] NICKRENT DL. Parasitic Plants of the World. in: López-Sáez, J.A.; Catalán, P.; Sáez, L. (eds), *Parasitic Plants of the Iberian Peninsula and Balearic Islands*. Madrid. Mundi-Prensa Libros, 2002.
- [58] Oei SL, Thronicke A, Kröz M, von Trott P, Schad F, Matthes H. Impact of Oncological Therapy and *Viscum album L* Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients. *Integr Cancer Ther.* 2020 Jan-Dec.
- [59] Oei SL, Thronicke A, Schad F. Mistletoe and Immunomodulation: insights and implications for anti-cancer therapies. *Evidence-Based Complementary And Alternative Medicine*, [S.L.], 17 abr. 2019, v. 2019, p. 1-6.
- [60] Orhan DD, Küpeli E, Yesilada E, Ergun F. Anti-inflammatory and antinociceptive activity of flavonoids isolated from *Viscum album ssp. album*. *Z Naturforsch C J Biosci.*, [S.I], fev. 2006, v. 61, n. 1-2, p. 26-30.
- [61] Orrù S, Scaloni A, Giannattasio M, Urech K, Pucci P, Schaller G. Amino acid sequence, S-S bridge arrangement and distribution in plant tissues of thionins from *Viscum album*. *Biol Chem*, [S.I], out. 1997, v. 378, n. 9, p. 989-996.
- [62] Park WB, Lyu SY, Kim JH, Choi SH, Chung HK, Ahn SH, Hong SY, Yoon TJ. Inhibition of Tumor Growth and Metastasis by Korean Mistletoe Lectin is Associated with Apoptosis and Antiangiogenesis. *Mary Ann Liebert Inc. Cancer Biotherapy And Radiopharmaceuticals*, [S.L.], out. 2001, v. 16, n. 5,

- p. 439-447.
- [63] Panossian A, Kocharian A, Matinian K, Amroyan E, Gabrielian E, Chr, et al. Pharmacological activity of phenylpropanoids of the mistletoe, *Viscum album* L., host: *pyruscaucasica* fed. Elsevier BV. Phytomedicine, [S.L.], mar. 1998, v. 5, n. 1, p. 11-17.
- [64] Panunto-Castelo A, Souza MA, Roque-Barreira MC, Silva JS. KM+, a lectin from *Artocarpus integrifolia*, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against *Leishmania major* antigens, resulting in BALB/c mice resistance to infection. Oxford University Press (OUP). Glycobiology, [S.L.], 1 dez. 2001, v. 11, n. 12, p. 1035-1042.
- [65] Reynel M, Villegas Y, Kiene H, Werthmann PG, Kienle GS. Intralesional and subcutaneous application of *Viscum album* L. (European mistletoe) extract in cervical carcinoma in situ. Ovid Technologies (Wolters Kluwer Health). Medicine, [S.L.], nov. 2018, v. 97, n. 48, p. 1-6.
- [66] Rostock M. Die Misteltherapie in der Behandlung von Patienten mit einer Krebserkrankung. Springer Link, [S.I.], mar. 2020, v. 63, n. -, p. 535-540.
- [67] Rubiales D, Heide-Jørgensen HS. Parasitic Plants. Els Subject Area: Plant Science, [S.I.], 15 fev. 2011, v. -, n. -, p. 1-10.
- [68] Schaller G, Urech K, Giannattasio M. Cytotoxicity of Different Viscotoxins and Extracts from the European Subspecies of *Viscum album* L. Phytotherapy Research, [S.L.], set. 1996, v. 10, n. 6, p. 473-477.
- [69] Senthilkumar B, Rajasekaran R. In Silico Template Selection of Short Antimicrobial Peptide Viscotoxin for Improving Its Antimicrobial Efficiency in Development of Potential Therapeutic Drugs. ApplBiochemBiotechnol. 2017 Mar, v. 181, n.3, p. 898-913.
- [70] Sárpatoki O, Sevastre B, Stan R, Olah N, Hanganu D, Bedecan I, Ionescu C, Marcus I. *Viscum Album* L. Influence on the Antioxidant Enzymes Activity in Ehrlich Tumor Cells In Vivo. Bull Univ Agric Sci Vet Med Cluj-Napoca - Vet Med. 2014, v. 71, n. 1, p. 198-203.
- [71] Schad F, Atxner J, Buchwald D, Happe A, Popp S, Kröz M, Matthes H. Intratumoral Mistletoe (*Viscum album* L) Therapy in Patients With Unresectable Pancreas Carcinoma. Integrative Cancer Therapies, [S.L.], 19 dez. 2013, v. 13, n. 4, p. 332-340.
- [72] Schaller G, Urech K, Giannattasio M. Cytotoxicity of Different Viscotoxins and Extracts from the European Subspecies of *Viscum album* L. Phytotherapy Research, [S.L.], set. 1996, v. 10, n. 6, p. 473-477.
- [73] Schötterl S, Miemietz JT, Ilina EI, Wirsik NM, Ehrlich I, Gall A, et al. Mistletoe-Based Drugs Work in Synergy with Radio- Chemotherapy in the Treatment of Glioma *In Vitro* and *In Vivo* in Glioblastoma Bearing Mice. Evidence-Based Complementary And Alternative Medicine, [S.L.], 3 jul. 2019, v. 2019, p. 1-17.
- [74] Stammer RM, Kleinsimon S, Rolff J, Jäger S, Eggert A, Seifert G, et al. Synergistic Antitumour Properties of *viscum* T in Alveolar Rhabdomyosarcoma. Journal Of Immunology Research, [S.L.], 2017, v. 2017, p. 1-13.
- [75] Stein G M, Berger P A. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. European Journal of Medical Research, 1999, v. 4n. 5, p. 169-177.
- [76] Steinborn C, Klemd AM, Sanchez-Campillo AS, Rieger S, Scheffén M, Sauer B, Garcia-Käufer M, Urech K, Follo M, Ücker A, Kienle GS, Huber R, Gründemann C. *Viscum album* neutralizes tumor-induced immunosuppression in a human in vitro cell model. Plos One., [s. l], 18 jul. 2017, v. 12, n. 7, p. 1-18.
- [77] Strüh CM, Jäger S, Kersten A, Schempp CM, Scheffler A, Martin SF. Triterpenoids Amplify Anti-Tumoral Effects of Mistletoe Extracts on Murine B16.F10 Melanoma In Vivo. Public Library of Science (PLOS). Plos One, [S.L.], 17 abr. 2013, v. 8, n. 4, p. 1-10.
- [78] Strüh CM, Jäger S, Schempp CM, Scheffler A, Martin SF. A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytotherapy Res, [S.I.], out. 2012, v. 26, n. 10, p. 1507-1512.
- [79] Szurpnicka A, Zjawiony JK, Szterk A. Therapeutic potential of mistletoe in CNS-related neurological disorders and the chemical composition of *Viscum* species. J Ethnopharmacol, [s. l], mar. 2019, v. 231, n. 1, p. 241-252.
- [80] Souza MA, Carvalho FC, Ruas LP, Ricci-Azevedo R, Roque-Barreira MC. The immunomodulatory effect of plant lectins: a review with emphasis on artimn properties. Springer Science and Business Media LLC. Glycoconjugate Journal, [S.L.], 9 jan. 2013, v. 30, n. 7, p. 641-657. Tabiasco J, Pont F, Fournié J-J, Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. European Journal Of Biochemistry, [S.L.], 9 maio 2002, v. 269, n. 10, p. 2591-2600.
- [81] Twardziok M, Meierhofer D, Börno S, Timmermann B, Jäger S, Boral S, et al. Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses. Bmc Complement Altern Med., [S.I.], abr. 2017, v. 17, n. 1, p. 1-14.
- [82] Urech K, Buessing A, Thalmann G, Schaefermeyer H, Heusser P. Antiproliferative effects of mistletoe (*Viscum album* L.) extract in urinary bladder carcinoma cell lines. Anticancer Res, [S.I.], ago. 2006, v. 26, n. 4, p. 3049-3055.
- [83] Urech K, Baumgartner S. Chemical Constituents of *Viscum album* L.: Implications for the Pharmaceutical Preparation of Mistletoe. Mistletoe: From Mythology To Evidence-Based Medicine, [S.I.], 2015, v. 4, n. -, p. 11-23.
- [84] Van Wely M, Stoss M, Gorter RW. Toxicity of a Standardized Mistletoe Extract in Immunocompromised and Healthy Individuals. Ovid Technologies (Wolters Kluwer Health). American Journal Of Therapeutics, [S.L.], jan. 1999, v. 6, n. 1, p. 37-44.
- [85] Valle ACV. Antimicrobial activity of proteins from jambolan (*Syzygium cumini* (L.) Skeels) seeds. Master Thesis in Animal Science, 2008; União

- Pioneira de Integração Social, Brasília, Brazil. 89p.
- [86] Valle ACV, Andrade R V, Sibata MN, Carvalho AC. Ultradiluted *Viscum album* in the Treatment of Melanoma in a Dog (*Canis familiaris*) – Case Report. Homeopatia, 2020, v. 109, n. 01, p. A1-A28.
- [87] Valle ACV, Sibata MN, Andrade RV, Carvalho AC. Homeopathy for the Treatment of Transmissible Venereal Tumor (TVT) in a Mixed-Breed Female Dog. Adv Complement Alt Med. 2019, v. 5, n. 1.
- [88] Valle ACV, Lima L, Andrade RA, Bonamin L, Brunel H, et al. Use of *Viscum album* in the Integrative Treatment of Cholangiocarcinoma in a Dog (*Canis familiaris*) - Case Report. Adv Complement Alt Med. 2020, v. 5, n. 4.
- [89] ZONE, The Biology. Viscaceae - Mistletoe Family. Disponível em: <<http://www.thebiologyzone.com/viscaceae-mistletoe-family.html>>. Acesso em: 02 nov. 2020.
- [90] Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z, Hai C. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK– p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. Oxford University Press (OUP). Carcinogenesis, [S.L.], 12 fev. 2013, v. 34, n. 6, p. 1323-1330.
- [91] Wacker R, Stoeva S, Pfüller K, Pfüller U, Voelter W. Complete structure determination of the A chain of mistletoe lectin III from *Viscum album* L. ssp. *album*. Journal Of Peptide Science, [S.L.], 10 nov. 2003, v. 10, n. 3, p. 138- 148.
- [92] Wagner H, Bladt S, Zgainski EM. Plant Drug Analysis, New York: Springer-Verlag, 1984, 320 p.
- [93] Wagner H, Feil B, Seligmann O, Petricic J, Kalogjera Z. Phenylpropanes and lignans of *Viscum album* cardioactive drugs V. Planta Med., [S.I.], 2 abr. 1986, p. 102-104.
- [94] Wei J, Liu M, Liu H, Wang H, Wang F, Zhang Y, Han L, Lin X. Oleanolic acid arrests cell cycle and induces apoptosis via ROS-mediated mitochondrial depolarization and lysosomal membrane permeabilization in human pancreatic cancer cells. Journal Of Applied Toxicology, [S.I.], 8 jun. 2013, v. 33, n. 8, p. 756-765.
- [95] Werthmann PG, Inter P, Welsch T, Sturm AK, Grützmann R, Debus M, Sterner MG, Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing *Viscum album* extracts and subsequent R0 resection. Ovid Technologies (Wolters Kluwer Health). Medicine, [S.L.], dez. 2018, v. 97, n. 49, p. 1-6.
- [96] Werthmann PG, Kindermann L, Kienle GS. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with *Viscum album* Extracts. Complement Med Res, [S.I.], mar. 2019, v. 26, n. 4, p. 276-279.
- [97] Weissenstein U, Kunz M, Urech K, Baumgartner S. Interaction of standardized mistletoe (*Viscum album*) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Springer Science and Business Media LLC. Complementary and Alternative Medicine, [S.L.], 8 jan. 2014, v. 14, n. 1, p. 1-9.
- [98] Werthmann PG, Hintze A, Kienle GS. Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing *Viscum album* extract. Ovid Technologies (Wolters Kluwer Health). Medicine, [S.L.], nov. 2017 v. 96, n. 46, p. 1-6.
- [99] Wollenweber E, Wieland A, Haas K. Epicuticular Waxes and Flavonol Aglycones of the European Mistletoe, *Viscum album* L. Walter de Gruyter GmbH. Zeitschrift Für Naturforschung C, [S.L.], 1 jun. 2000, v. 55, n. 5- 6, p. 314-317.
- [100] Yang X, Jiang S, Liu Y, Zhang P, Xie S, Wang G. Recombinant VAA-I from *Viscum album* Induces Apoptotic Cell Death of Hepatocellular Carcinoma SMMC7721 Cells. Molecules, [S.I.], jun. 2012, v. 17, n. 10, p. 11435-11446.
- [101] Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, et al. Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Nature, [s. l.], 23 abr. 2019, v. 6428, n. 9, p. 1-12.
- [102] Unger G. Kurze Geschichte der Heilmittelzentrifuge des Institutes Hirsch unter Einbeziehung der Hinweise Rudolf Steiners zur Herstellung der Mistelpräparate. In: Misteltherapie - Eine Antwort Auf Die Herausforderung Krebs. Vol Mistelther. 1987:1-259.